Nevertheless, recent clinical trial with CAR T-cells targeting HER2 demonstrated that 17 participants including pediatric patients with progressive HER2-positive glioblastoma achieved 11.1 months and 24.5 months of overall survival after CAR T-cells infusion and after diagnosis, respectively. Here, ERBB2 is linked to glioblastoma.